Biologic Therapy for Inflammatory Bowel Disease

被引:0
作者
Sandro Ardizzone
Gabriele Bianchi Porro
机构
[1] “L. Sacco” University Hospital,Cattedra e Divisione di Gatroenterologia, ed Endoscopia Digestiva, Azienda Ospedaliera “L. Sacco”
[2] Polo Universitario,undefined
来源
Drugs | 2005年 / 65卷
关键词
Inflammatory Bowel Disease; Ulcerative Colitis; Infliximab; Natalizumab; Mucosal Healing;
D O I
暂无
中图分类号
学科分类号
摘要
Despite all of the advances in our understanding of the pathophysiology of inflammatory bowel disease (IBD), we still do not know its cause. Some of the most recently available data are discussed in this review; however, this field is changing rapidly and it is increasingly becoming accepted that immunogenetics play an important role in the predisposition, modulation and perpetuation of IBD. The role of intestinal milieu, and enteric flora in particular, appears to be of greater significance than previously thought. This complex interplay of genetic, microbial and environmental factors culminates in a sustained activation of the mucosal immune and non-immune response, probably facilitated by defects in the intestinal epithelial barrier and mucosal immune system, resulting in active inflammation and tissue destruction.
引用
收藏
页码:2253 / 2286
页数:33
相关论文
共 612 条
[1]  
Ferguson A(1994)Ulcerative colitis and Crohn’s disease: important and disabling diseases, still under-researched BMJ 309 355-6
[2]  
Hanauer SB(2003)The state of the art in the management of inflammatory bowel disease Rev Gastroenterol Disord 3 81-92
[3]  
Present DH(2001)Practice Parameters Committee of the American College of Gastroenterology: management of Crohn’s disease in adults Am J Gastroenterol 96 635-43
[4]  
Hanauer SB(2003)Review article: mild to moderate Crohn’s disease: defining the basis for a new treatment algorithm Aliment Pharmacol Ther 18 263-77
[5]  
Sandborn WJ(1997)Mesalamine in the maintenance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variables Gastroenterology 113 1465-73
[6]  
Sandborn WJ(2000)Prophylaxis of postoperative relapse in Crohn’s disease: European Cooperative Crohn’s Disease Study VI Gastroenterology 18 264-73
[7]  
Feagan BG(1999)Medical therapy for inflammatory bowel disease Gastroenterol Clin North Am 28 297-321
[8]  
Camma C(2001)The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study Gastroenterology 123 255-60
[9]  
Giunta M(1997)Azathioprine in steroid-dependent ulcerative colitis J Clin Gastroenterol 26 330-3
[10]  
Rosselli M(1995)Azathioprine and 6-mercaptopurine in Crohn’s disease: a meta-analysis Ann Intern Med 123 132-42